Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biotest AG (BIO) NPV

Sell:€43.30 Buy:€43.80 Change: €0.60 (1.37%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: €0.60 (1.37%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: €0.60 (1.37%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Contact details

Landsteinerstr. 5
+49 (6103) 8010

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€1.64 billion
Shares in issue:
39.57 million
Frankfurt Stock Exchange

Key personnel

  • Rolf Hoffmann
    Chairman of the Supervisory Board
  • Michael Ramroth
    Chairman of the Management Board, Chief Executive Officer/Chief Financial Officer
  • Tan Yang
    Deputy Chairman of the Supervisory Board
  • Martin Moeller
    Group Finance and Treasury Officer
  • Georg Floss
    Chief Operating Officer, Member of the Management Board
  • Oliver Hein
    Corporate Risk and Compliance Officer
  • Stephan Fleck
    Corporate Controlling
  • Enrico D'aiuto
    Global Sales
  • Christina Erb
    Head of Human Resources
  • Josefine Buth
    Head of Corporate Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.